Novartis has thrown its weight behind a “Cinderella antibody,” leading a 30.8 million pound sterling ($40.9 million) series B round that positions Epsilogen to try to create “a brand new category of pharmaceutical within within cancer.” London-based Epsilogen’s primary focus is an immunoglobulin E (IgE) antibody that targets the folate receptor alpha antigen. Source: Fierce Biotech 2/3/22